ARTICLE | Clinical News
Optivax synthetic copolymer: Vaxcel began a Phase I trial
February 5, 1996 8:00 AM UTC
Patients will be given four doses a month apart, beginning with 3 mg and escalating up to 70 mg. Optivax acts both as a delivery system by targeting vaccines to immune system cells, and as an adjuvant...